Therefore, favouring the interaction between RBM25 and the GQ-2 rG4 of BCL-x pre-mRNA represents a relevant intervention point to re-sensitize cancer cells to chemotherapy, whereas interfering with this interaction may represent a therapeutic avenue for diseases associated with Bcl-xS overexpression, such as some forms of diabetes. The gene discussed is BCL2L1; the disease is cancer.